Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma

October 14th 2025

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma

October 13th 2025

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

October 13th 2025

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

October 9th 2025

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Randall on the Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance

October 9th 2025

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

Dr Tarantino on the CompassHER2 pCR Trial of THP in HER2+ Breast Cancer

October 9th 2025

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients

October 9th 2025

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology

October 9th 2025

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

October 8th 2025

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy

October 8th 2025

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma

October 8th 2025

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.

Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis

October 8th 2025

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Dr Sampath on the Safety of Consolidative Radiotherapy Plus Osimertinib in Advanced EGFR-Mutant NSCLC

October 7th 2025

Sagus Sampath, MD, discusses the safety profile of consolidative radiotherapy administered in conjunction with osimertinib in advanced EGFR-mutant NSCLC

Dr Qiu on the Efficacy and Safety of Eque-Cel in Relapsed/Refractory Multiple Myeloma

October 7th 2025

Luqui Qiu, MD, discusses the efficacy and safety of eque-cel in patients with relapsed or refractory multiple myeloma.

Dr Mouhieddine on a Study of Correlates of Response to Bispecific Antibodies in Myeloma

October 7th 2025

Tarek Mouhieddine, MD, discusses the background and design of a study of correlates of response to bispecific antibodies in relapsed/refractory myeloma.

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer

October 7th 2025

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma

October 7th 2025

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.